NCT05919537View on ClinicalTrials.gov

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

March 1, 2031

Study Completion Date

March 1, 2031

Conditions
Non-Small Cell Lung CancerPancreatic CancerLocally Advanced Solid TumorMetastatic Solid Tumor
Interventions
DRUG

HMBD-001

HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly

DRUG

Docetaxel

Docetaxel 75 mg/m\^2 IV once every 3 weeks

DRUG

Nab-paclitaxel

Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks

DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks

Trial Locations (5)

2065

GenesisCare North Shore, Sydney

3144

Cabrini Health, Malvern

4101

ICON Cancer Centre South Brisbane, Brisbane

5042

Southern Oncology Clinical Research Unit, Adelaide

6009

Linear Clinical Research, Perth

Sponsors
All Listed Sponsors
lead

Hummingbird Bioscience

INDUSTRY